IRIS
PERNO, CARLO-FEDERICO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 142.605
AS - Asia 15.725
EU - Europa 14.575
SA - Sud America 2.551
AF - Africa 369
OC - Oceania 134
Continente sconosciuto - Info sul continente non disponibili 45
Totale 176.004
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 142.140
SG - Singapore 7.824
CN - Cina 2.724
DE - Germania 2.132
RU - Federazione Russa 2.119
BR - Brasile 2.082
UA - Ucraina 1.871
IT - Italia 1.539
HK - Hong Kong 1.487
SE - Svezia 1.370
IE - Irlanda 1.230
VN - Vietnam 1.224
FI - Finlandia 1.092
FR - Francia 1.009
GB - Regno Unito 768
PL - Polonia 726
KR - Corea 704
JP - Giappone 374
CA - Canada 270
IQ - Iraq 267
IN - India 226
AR - Argentina 170
ID - Indonesia 161
NL - Olanda 142
AU - Australia 131
BD - Bangladesh 126
ZA - Sudafrica 109
MX - Messico 107
BE - Belgio 105
AT - Austria 99
TR - Turchia 97
ES - Italia 92
EC - Ecuador 87
CZ - Repubblica Ceca 86
PK - Pakistan 72
IR - Iran 65
PH - Filippine 65
CO - Colombia 45
CL - Cile 44
UZ - Uzbekistan 43
VE - Venezuela 40
CM - Camerun 34
EU - Europa 34
KE - Kenya 34
MA - Marocco 34
CH - Svizzera 32
AE - Emirati Arabi Uniti 31
PY - Paraguay 28
EG - Egitto 25
RO - Romania 25
SA - Arabia Saudita 25
TN - Tunisia 25
PE - Perù 23
DZ - Algeria 22
IL - Israele 22
LT - Lituania 21
NP - Nepal 21
JO - Giordania 19
JM - Giamaica 18
MY - Malesia 18
GR - Grecia 16
KZ - Kazakistan 16
UY - Uruguay 15
BG - Bulgaria 14
BO - Bolivia 14
KG - Kirghizistan 14
PT - Portogallo 14
AZ - Azerbaigian 13
DK - Danimarca 12
TH - Thailandia 12
HU - Ungheria 11
TW - Taiwan 11
ET - Etiopia 10
GH - Ghana 10
LB - Libano 10
NG - Nigeria 10
CR - Costa Rica 9
DO - Repubblica Dominicana 9
HN - Honduras 9
LK - Sri Lanka 9
CI - Costa d'Avorio 8
DM - Dominica 8
OM - Oman 8
TT - Trinidad e Tobago 8
AL - Albania 7
GT - Guatemala 7
PS - Palestinian Territory 7
A2 - ???statistics.table.value.countryCode.A2??? 6
AO - Angola 6
BY - Bielorussia 6
RS - Serbia 6
HR - Croazia 5
LY - Libia 5
MN - Mongolia 5
PA - Panama 5
QA - Qatar 5
SK - Slovacchia (Repubblica Slovacca) 5
SN - Senegal 5
UG - Uganda 5
BB - Barbados 4
Totale 175.914
Salva come PNG Salva come JPEG
Città #
Woodbridge 41.750
Wilmington 36.809
Houston 32.041
Singapore 4.123
Fairfield 3.939
Ann Arbor 3.352
Ashburn 2.497
Chandler 1.981
San Jose 1.848
Jacksonville 1.678
Seattle 1.661
Hong Kong 1.464
Cambridge 1.358
Dublin 1.162
Beijing 1.090
Medford 911
Santa Clara 678
Dearborn 668
Helsinki 667
Council Bluffs 653
Kraków 626
Moscow 534
Rome 518
The Dalles 493
Los Angeles 484
New York 484
Dallas 432
Lawrence 429
Ho Chi Minh City 371
Tokyo 314
Hanoi 298
Mülheim 270
Buffalo 249
São Paulo 219
San Diego 211
Milan 207
Menlo Park 206
Lauterbourg 191
Zhengzhou 161
Munich 151
Orem 126
Nuremberg 121
London 119
Jakarta 116
Boardman 108
Falls Church 106
Chicago 105
Phoenix 102
Brussels 100
University Park 86
San Francisco 83
Redwood City 79
Dong Ket 78
Frankfurt am Main 78
Palo Alto 76
Baghdad 75
Norwalk 75
Guangzhou 70
Chennai 67
Warsaw 67
North Bergen 66
Toronto 66
Mountain View 65
Rio de Janeiro 65
Shanghai 64
Nanjing 62
Redondo Beach 62
San Mateo 62
Montreal 60
Creede 59
Amsterdam 58
Porto Alegre 58
Verona 58
Columbus 56
Haiphong 55
Johannesburg 54
Atlanta 52
Brooklyn 50
Brno 49
Denver 48
Poplar 47
Saint Petersburg 44
Hefei 42
Vienna 41
Da Nang 40
Kunming 40
Boston 39
Stockholm 39
Vancouver 39
Lappeenranta 37
Sydney 37
Melbourne 36
Belo Horizonte 35
Brasília 34
Sulaymaniyah 33
Tashkent 32
Colorado Springs 31
Curitiba 31
Olomouc 31
Guayaquil 30
Totale 150.922
Salva come PNG Salva come JPEG
Nome #
1,2,3-TRIAZOLE-[2',5'-BIS-O-(TERT-BUTYLDIMETHYLSILYL)-BETA-D-RIBOFURANOSYL]-3'-SPIRO-5''-(4''-AMINO-1'',2''-OXATHIOL 2'',2''-DIOXIDE) (TSAO) ANALOGS - SYNTHESIS AND ANTI-HIV-1 ACTIVITY 1.101
Antibiotic susceptibility of vancomyin and nitrofurantoin in Staphylococcus aureus isolated from burnt patients in Sulaimaniyah, Iraqi Kurdistan 765
Is there any potential for first-line etravirine use? Analysis from a large data set of antiretroviral therapy-naive HIV-infected patients undergoing resistance test 594
HCV NS3 sequencing as a reliable and clinically useful tool for the assessment of genotype and resistance mutations for clinical samples with different HCV-RNA levels 577
Persistent risk of HBV reactivation despite extensive lamivudine prophylaxis in haematopoietic stem cell transplant recipients who are anti-HBc-positive or HBV-negative recipients with an anti-HBc-positive donor 574
Lower prevalence of drug resistance mutations at first-line virological failure to first-line therapy with atripla vs. tenofovirRemtricitabine/lamivudineRefavirenz administered on a multiple tablet therapy 569
Description of the L76V resistance protease mutation in HIV-1 B and "non-B" subtypes 568
Molecular and structural aspects of clinically relevant mutations related to the approved non-nucleoside inhibitors of HIV-1 reverse transcriptase 547
KI and WU polyomaviruses and CD4+ cell counts in HIV-1-infected patients, Italy 540
Occupational HIV infection in a research laboratory with unknown mode of transmission: a case report 533
The Genotypic False Positive Rate Determined by Population V3-Sequencing can Predict the Burden of X4 Quasispecies Detected by Pyrosequencing 532
Progesterone and Melanoma Cells: An Old Story Suspended between Life and Death 531
Characterization and structural analysis of novel mutations in human immunodeficiency virus type 1 reverse transcriptase involved in the regulation of resistance to nonnucleoside inhibitors 528
A killer mimotope with therapeutic activity against AIDS-related opportunistic micro-organisms inhibits ex-vivo HIV-1 replication 525
HCV-RNA quantification in liver bioptic samples and extrahepatic compartments, using the abbott RealTime HCV assay 519
Treatment with the fusion inhibitor enfuvirtide influences the appearance of mutations in the human immunodeficiency virus type 1 regulatory protein rev 518
The novel swine-origin H1N1 influenza A virus riddle: is it a domestic bird H1N1-derived virus? 513
Therapeutic strategies towards HIV-1 infection in macrophages 510
Snapshot on drug-resistance rate and profiles in patients with chronic hepatitis B receiving nucleos(t)ide analogues in clinical practice 507
Comparative Analysis of Drug Resistance Among B and the Most Prevalent Non-B HIV Type 1 Subtypes (C, F, and CRF02_AG) in Italy 506
Carbohydrate-binding agents (CBAs) inhibit HIV-1 infection in human primary monocyte-derived macrophages (MDMs) and efficiently prevent MDM-directed viral capture and subsequent transmission to CD4(+) T lymphocytes 505
Comparative antiviral activity of integrase inhibitors in human monocyte-derived macrophages and lymphocytes 505
The lowest X4 Geno2Pheno false-positive rate is associated with greater CD4 depletion in HIV-1 infected patients 504
Characterization of drug-resistance mutations in HIV-1 isolates from non-HAART and HAART treated patients in Burkina Faso 504
Virologic correlates of adherence to antiretroviral medications and therapeutic failure 500
A multi-targeted drug candidate with dual anti-HIV and anti-HSV activity 498
Activity of the (R)-Enantiomers of 9-(2-phosphonylmethoxypropyl)-adenine and 9-(2-phosphonylmethoxypropyl)-2,6-diaminopurine against human immunodeficiency virus in different human cell systems 496
A multicenter evaluation of the Abbott RealTime HCV Genotype II assay 494
Safety of complete and sustained prophylaxis withdrawal in patients liver-transplanted for HBV-related cirrhosis at low risk of HBV recurrence 493
Two different patterns of mutations are involved in the genotypic resistance score for atazanavir boosted versus unboosted by ritonavir in multiple failing patients 491
Early antiretroviral treatment (eART) limits viral diversity over time in a long-term HIV viral suppressed perinatally infected child 491
Epidemiological network analysis in HIV-1 B infected patients diagnosed in Italy between 2000 and 2008 490
Potential for new antiretrovirals to address unmet needs in the management of HIV-1 infection 489
Understanding HIV compartments and reservoirs 488
Influenza virus A (H5N1): A pandemic risk? 487
Novel HBsAg mutations correlate with hepatocellular carcinoma, hamper HBsAg secretion and promote cell proliferation in vitro 487
HIV fitness and resistance as covariates associated with the appearance of mutations under antiretroviral treatment 486
'Sentinel' mutations in standard population sequencing can predict the presence of HIV-1 reverse transcriptase major mutations detectable only by ultra-deep pyrosequencing 485
Hepatitis B surface antigen genetic elements critical for immune escape correlate with hepatitis B virus reactivation upon immunosuppression 485
Ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir, plus ribavirin for patients with hepatitis C virus genotype 1 or 4 infection with cirrhosis (ABACUS): a prospective observational study 485
Mannose-specific plant lectins from the Amaryllidaceae family qualify as efficient microbicides for prevention of human immunodeficiency virus infection 484
Advances in macrophage and dendritic cell biology in HIV-1 infection stress key understudied areas in infection, pathogenesis, and analysis of viral reservoirs 484
Kinetics of hepatitis C virus RNA decay, quasispecies evolution and risk of virological failure during telaprevir-based triple therapy in clinical practice 484
Hepatitis C virus RNA levels at week-2 of telaprevir/boceprevir administration are predictive of virological outcome 484
Correlation between induction of lymphocyte apoptosis and prostaglandin E2 production by macrophages infected with HIV 483
Viral causes of influenza-like illness: Insight from a study during the winters 2004-2007 483
Thymosin α 1 potentiates the release by CD8(+) cells of soluble factors able to inhibit HIV-1 and human T lymphotropic virus 1 infection in vitro 483
Nucleotide polymorphisms in the 5'-UTR region of HCV can affect the ability of two widely used assays to assign an HCV genotype 482
Viro-immunological response of drug-naive HIV-1-infected patients starting a first-line regimen with viraemia >500,000 copies/ml in clinical practice 481
Thymosin alpha 1 and HIV-1: Recent advances and future perspectives 481
Mechanisms underlying activity of antiretroviral drugs in HIV-1-infected macrophages: New therapeutic strategies 479
Drug-resistance development differs between HIV-1-infected patients failing first-line antiretroviral therapy containing nonnucleoside reverse transcriptase inhibitors with and without thymidine analogues 479
Characterization of drug-resistance mutations in HBV D-genotype chronically infected patients, naïve to antiviral drugs. 479
48 week outcomes of maraviroc-containing regimens following the genotypic or Trofile assay in HIV-1 failing subjects: the OSCAR Study 479
Lamivudine-resistance mutations can be selected even at very low levels of hepatitis B viraemia 477
Novel drug resistance mutations in HIV: Recognition and clinical relevance 475
Red blood cells mediated delivery of 9-(2-phosphonylmethoxyethyl)adenine to primary macrophages: Efficiency, metabolism and activity against human immunodeficiency virus or herpes simplex virus 475
Immunomodulatory activity of 9-(2-phosphonyl-methoxyethyl)adenine (PMEA), a potent anti-HIV nucleotide analogue, on in vivo murine models 475
HIV-1-associated dementia during HAART therapy 475
Effect of maraviroc on non-R5 tropic HIV-1: Refined analysis of subjects from the phase IIb study A4001029 474
Characterization of the patterns of drug-resistance mutations in newly diagnosed HIV-1 infected patients naive to the antiretroviral drugs 474
Potent inhibition of human immunodeficiency virus and herpes simplex virus type 1 by 9-(2-phosphonylmethoxyethyl)adenine in primary macrophages is determined by drug metabolism, nucleotide pools, and cytokines 473
Molecular analysis based on mtLSU-rRNA and DHPS sequences of Pneumocystis jirovecii from immunocompromised and immunocompetent patients in Italy 473
Specific mutations in the C-terminus domain of HBV surface antigen significantly correlate with low level of serum HBV-DNA in patients with chronic HBV infection 473
Involvement of novel human immunodeficiency virus type 1 reverse transcriptase mutations in the regulation of resistance to nucleoside inhibitors 472
Comparative evaluation of subtyping tools for the surveillance of newly emerging HIV-1 strains 472
Human immunodeficiency virus infection and acquired immunodeficiency syndrome dementia complex: Role of cells of monocyte-macrophage lineage 471
Effective program against mother-to-child transmission of HIV at Saint Camille Medical Centre in Burkina Faso 471
Risk of failure in patients with 215 HIV-1 revertants starting their first thymidine analog-containing highly active antiretroviral therapy 469
Identification of the novel KI polyomavirus in the respiratory tract of an Italian patient 468
Late-onset hemorrhagic cystitis in children after hematopoietic stem cell transplantation for thalassemia and sickle cell anemia: a prospective evaluation of polyoma (BK) virus infection and treatment with cidofovir 468
Successful switch to tenofovir after suboptimal response to entecavir in an immunocompromised patient with chronic hepatitis B and without genotypic hepatitis B virus resistance. 468
Viro-immunologic response to ritonavir-boosted or unboosted atazanavir in a large cohort of multiply treated patients: the CARe Study 468
Nerve growth factor is an autocrine factor essential for the survival of macrophages infected with HIV 467
Macrophages and HIV infection: Therapeutical approaches toward this strategic virus reservoir 466
Glutathione inhibits HIV replication by acting at late stages of the virus life cycle 465
Population dynamics of HIV-1 subtype B in a cohort of men-having-sex-with-men in Rome, Italy 465
Macrophage depletion induced by clodronate-loaded erythrocytes 465
Impact of HIV-1 reverse transcriptase polymorphism F214L on virological response to thymidine analogue-based regimens in antiretroviral therapy (ART)-naive and ART-experienced patients 463
Telomerase activity, hTERT expression, and phosphorylation are downregulated in CD4(+) T lymphocytes infected with human immunodeficiency virus type 1 (HIV-1) 463
Specific enfuvirtide-associated mutational pathways in HIV-1 Gp41 are significantly correlated with an increase in CD4(+) cell count, despite virological failure 463
Impact of different HIV resistance interpretation by distinct systems on clinical utility of resistance testing. 462
A case of Italian HIV-2 infection: a genetic analysis 462
Characterization of novel HIV drug resistance mutations using clustering, multidimensional scaling and SVM-based feature ranking 461
Primary macrophages infected by human immunodeficiency virus trigger CD95-mediated apoptosis of uninfected astrocytes 461
Monitoring of KI and WU polyomaviruses in hematopoietic stem cell transplant patients 460
Specific HIV-1 integrase polymorphisms change their prevalence in untreated versus antiretroviral-treated HIV-1-infected patients, all naive to integrase inhibitors 458
Anti-nerve growth factor Ab abrogates macrophage-mediated HIV-1 infection and depletion of CD4+ T lymphocytes in hu-SCID mice 457
Role of hepatitis B virus genetic barrier in drug-resistance and immune-escape development 457
Optimal efficacy of interferon-free HCV retreatment after protease inhibitors failure in real life. 457
Drug-loaded red blood cell-mediated clearance of HIV-1 macrophage reservoir by selective inhibition of STAT1 expression 456
Antiviral profile of HIV inhibitors in macrophages: Implications for therapy 456
Minor mutations in HIV protease at baseline and appearance of primary mutation 90M in patients for whom their first protease-inhibitor antiretroviral regimens failed 456
A boceprevir failure in a patient infected with HCV-genotype 1g: importance and limitations of virus genotyping prior to HCV protease inhibitor-based therapy 456
Structural modifications induced by specific HIV-1 protease-compensatory mutations have an impact on the virological response to a first-line lopinavir/ritonavir-containing regimen 455
When and how to use maraviroc in HIV-infected patients 454
Highly active antiretroviral therapy reduces the age-associated risk of dementia in a cohort of older HIV-1-infected patients 454
The multifactorial pathways towards resistance to the cytosine analogues emtricitabine and lamivudine: Evidences from literature 454
Inhibition of human immunodeficiency virus (HIV-1) infection in human peripheral blood leucocytes-SCID reconstituted mice by rapamycin 453
HCV genotypes are differently prone to the development of resistance to linear and macrocyclic protease inhibitors 453
Totale 49.535
Salva come PNG Salva come JPEG
Categoria #
all - tutte 380.788
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 380.788
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20211.199 0 0 0 0 0 0 0 0 0 0 823 376
2021/20225.019 233 358 337 253 210 523 206 179 764 480 232 1.244
2022/20235.987 665 415 201 716 465 1.332 426 454 482 110 498 223
2023/20242.031 267 195 142 72 258 344 88 83 55 89 35 403
2024/202511.964 417 2.601 1.198 655 364 688 1.213 536 1.077 714 1.402 1.099
2025/202617.877 1.391 873 2.267 1.592 1.531 811 2.543 2.703 2.220 1.866 80 0
Totale 177.298